Here, the FIGHT-202 study showed that treatment with pemigatinib, a selective, oral inhibitor of fibroblast growth factor receptor (FGFR) 1, 2 and 3, resulted in an objective response in previously treated CCA patients with detectable FGFR2 gene rearrangements; [13] a finding recently leading to authorisation of pemigatinib monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with the presence of a FGFR2 gene rearrangement that has progressed after at least one prior line of systemic therapy (EMEA/H/C/005266). Here, FGFR2 is linked to cholangiocarcinoma.